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The impact of the emergence of drug-resistance mutations on mortality is not well
characterized in antiretroviral-naı ¨ve patients first starting highly active antiretroviral therapy
(HAART). Patients may be able to sustain immunologic function with resistant virus, and there is
limited evidence that reduced sensitivity to antiretrovirals leads to rapid disease progression or
death. We undertook the present analysis to characterize the determinants of mortality in a
prospective cohort study with a median of nearly 5 y of follow-up. The objective of this study
was to determine the impact of the emergence of drug-resistance mutations on survival
among persons initiating HAART.
Methods and Findings
Participants were antiretroviral therapy naı ¨ve at entry and initiated triple combination
antiretroviral therapy between August 1, 1996, and September 30, 1999. Marginal structural
modeling was used to address potential confounding between time-dependent variables in the
Cox proportional hazard regression models. In this analysis resistance to any class of drug was
considered as a binary time-dependent exposure to the risk of death, controlling for the effect
of other time-dependent confounders. We also considered each separate class of mutation as a
binary time-dependent exposure, while controlling for the presence/absence of other
mutations. A total of 207 deaths were identified among 1,138 participants over the follow-
up period, with an all cause mortality rate of 18.2%. Among the 679 patients with HIV-drug-
resistance genotyping done before initiating HAART, HIV-drug resistance to any class was
observed in 53 (7.8%) of the patients. During follow-up, HIV-drug resistance to any class was
observed in 302 (26.5%) participants. Emergence of any resistance was associated with
mortality (hazard ratio: 1.75 [95% confidence interval: 1.27, 2.43]). When we considered each
class of resistance separately, persons who exhibited resistance to non-nucleoside reverse
transcriptase inhibitors had the highest risk: mortality rates were 3.02 times higher (95%
confidence interval: 1.99, 4.57) for these patients than for those who did not exhibit this type of
resistance.
Conclusions
We demonstrated that emergence of resistance to non-nucleoside reverse transcriptase
inhibitors was associated with a greater risk of subsequent death than was emergence of
protease inhibitor resistance. Future research is needed to identify the particular subpopu-
lations of men and women at greatest risk and to elucidate the impact of resistance over a
longer follow-up period.
The Editors’ Summary of this article follows the references.
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Post-surveillance cohort studies and long-term follow-up
studies of clinical trials, like the Merck 035 study, continue to
suggest the ongoing durability of highly active antiretroviral
therapy (HAART) [1–3]. Mortality among persons on these
three- or four-drug regimens continues to remain low, and
may be no higher than for other chronic diseases [4,5]. As one
large multinational study indicates, depending upon the
baseline characteristics of the persons initiating HAART,
subsequent disease progression and death can be as low as
2.4% at 3.5 y [4].
Emerging resistance poses a growing threat to the ongoing
success and durability of HAART regimens. Nearly 80% of
antiretroviral-treated patients with detectable viraemia in one
large US-based clinic study had evidence of phenotypic drug
resistance [6]. The frequency of resistance in this population-
based study was signiﬁcantly higher in patients with a history
of antiretroviral use, advanced HIV disease, higher plasma
HIV viral load, and the lowest CD4 cell counts. Continuing
viral replication during therapy leads to the accumulation of
drug-resistance mutations, resulting in increased viral load.
The current impact of the emergence of drug-resistance
mutations on mortality, however, is not well characterized in
antiretroviral-naı ¨ve patients ﬁrst starting HAART. Patients
may have sustained immunologic function with resistant virus
[7], and there is limited evidence that reduced sensitivity to
antiretrovirals leads to rapid disease progression or death [8].
Previously, we documented the selection of resistance in an
initially drug-naı ¨ve cohort starting HAART [9]. We therefore
undertook the present analysis to characterize the determi-
nants of mortality in this prospective cohort study with a
median of nearly 5 y of follow-up. The aim of this study was to
determine the impact of the emergence of drug-resistance
mutations on survival among persons initiating HAART.
Methods
HIV/AIDS Drug Treatment Program
The distribution and the population-based monitoring of
antiretroviral therapy in British Columbia have been exten-
sively described in the literature [10]. Since 1986, 6,305 HIV-
1-positive men and women have received antiretroviral
therapy. Prescriptions are distributed through several des-
ignated pharmacies or through one of the 1,200 or more
physicians who have ever prescribed antiretroviral therapy.
Although the majority of HIV-1-positive men and women
who have been given therapy are from Vancouver and the
surrounding region, eligible treatment recipients have come
from all regions in the province.
Since October 1992, the distribution of antiretrovirals has
been the responsibility of the HIV/AIDS Drug Treatment
Program of the British Columbia Centre for Excellence in
HIV/AIDS (the Centre). The Centre distributes antiretroviral
drugs based on guidelines generated by the Therapeutic
Guidelines Committee, which is made up of physicians,
pharmacists, virologists, health service researchers, and
economists [11]. The Centre’s HIV/AIDS Drug Treatment
Program has received ethical approval from the University of
British Columbia Ethics Review Committee at its St. Paul’s
Hospital site. The program also conforms with the province’s
Freedom of Information and Protection of Privacy Act.
Data Collection
All antiretroviral treatment recipients in the province are
entered into an Oracle-based monitoring and evaluation
reporting system that uses standardized indicators to pro-
spectively track the antiretroviral use and clinical and health
status of HIV-1-positive individuals. Physicians enrolling an
HIV-1-infected individual into the system must complete a
drug request enrolment prescription form, which compiles
information on the participant’s address, past HIV-speciﬁc
drug history, CD4 cell counts, plasma HIV-1 RNA, current
drug requests, and enrolling physician data. Typically,
persons receiving antiretroviral therapy are monitored by
physicians at intervals no longer than 3 mo, at which time
prescriptions are renewed or modiﬁed. At the time of the
initial dispensation, participants are asked to provide
informed consent for accessing medical electronic records
(which may be used for health utilization studies but are not
relevant to the analyses in this study) and to complete a
participant survey, which elicits information on sociodemo-
graphic characteristics, clinical and health status, and alter-
native therapy use. Both the consent form and the participant
survey are optional, and participant’s refusal to do either
does not limit his or her access to free antiretroviral therapy.
At the same time, the treating physicians are asked to
complete a clinical staging form using the World Health
Organization clinical staging system.
The Centre recommends that plasma HIV-1 RNA levels and
CD4 cell counts be monitored at baseline, at 4 wk after
starting antiretroviral therapy, and every 3 mo thereafter.
Plasma HIV-1 RNA levels were determined using the Roche
Amplicor Monitor assay (Roche Diagnostics, Laval, Quebec,
Canada) using either the standard method or the ultra-
sensitive adaptation. Plasma samples were stored chronolog-
ically as they were drawn and securely stored (frozen at  20
8C) for future use. CD4 cell counts were measured by ﬂow
cytometry, followed by ﬂuorescent monoclonal antibody
analysis (Beckman Coulter, Mississauga, Ontario, Canada).
Resistance testing was also completed on stored plasma
HIV-1 RNA samples [12–14]. HIV RNA was extracted from
plasma using the Qiagen (Huntsville, Alabama, United States)
viral RNA kit using a BioRobot 9600/9604 or extracted
manually using guanidinium-based buffer, followed by
isopropanol and ethanol washes. Protease and reverse tran-
scriptase genes were ampliﬁed from plasma HIV-1 RNA using
nested RT-PCR as described previously [15]. PCR products
were sequenced in both the 59 and 39 directions using an ABI
3700 or 3100 automated sequencer (Applied Biosystems,
Foster City, California, United States), and a consensus
sequence was generated. Results of the genotyping analysis
are reported as amino acid changes in the HIV protease and
reverse transcriptase sequences with respect to a wild-type
reference sequence (HIV HXB2).
Study Participants
All HIV-infected men and women in the current study were
entered into the Centre’s monitoring and evaluation system
when they were ﬁrst prescribed antiretroviral agents. Eligible
study participants were persons who were antiretroviral naı ¨ve
and were ﬁrst dispensed triple combination therapy between
August 1, 1996, and September 30, 1999. Participants must
also have had a CD4 count and plasma HIV-1 RNA measure-
ment within 6 mo of the ﬁrst antiretroviral start date. Study
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Centre’s monitoring and evaluation system to form the
HAART Observational Medical Evaluation and Research
(HOMER) cohort.
For all HOMER cohort participants, HIV drug resistance
genotyping was attempted on all samples with HIV-1 RNA
levels of 1,000 copies/ml or more collected in the ﬁrst 30 mo
following initiation of HAART. HIV isolates were assigned to
one of four resistance categories based on a modiﬁcation of
the International AIDS Society–USA table [11]. Samples were
considered resistant if they displayed one or more major
resistance mutations in one of four categories: lamivudine
(184I/V), any other nucleoside reverse transcriptase inhibitors
(41L, 62V, 65R, 67N, 69D or insertion, 70R, 74V, 75I, 151M,
210W, 215F/Y, or 219E/Q), any non-nucleoside reverse tran-
scriptase inhibitors (100I, 103N, 106A/M, 108I, 181C/I, 188C/
H/L, 190A/S, P225H, M230L, or 236L), and any protease
inhibitors (30N, 46I/L, 48V, 50L/V, 54V/L/M, 82A/F/S/T, 84V,
or 90M). Lamivudine resistance was analyzed as a separate
category because of the very common appearance of this
mutation and the lack of cross-resistance conferred to other
nucleoside reverse transcriptase inhibitors. As genotyping
does not yield consistently successful results on samples with
low viral loads, samples with HIV-1 RNA levels of less than
1,000 copies/ml were not systematically genotyped and were
assumed to have no drug resistance mutations.
Outcome Measures and Explanatory Variables
The primary endpoint in this analysis was all cause
mortality. Deaths occurring during the follow-up period
were identiﬁed on a continuous basis from physician reports
and through annual record linkages carried out with the
British Columbia Division of Vital Statistics.
The following explanatory variables were investigated: age,
gender, CD4 cell count, plasma HIV-1 RNA levels, prior AIDS
diagnosis, protease inhibitor use, current or past history of
injection drug use, physician experience, adherence, and
drug resistance. Physician experience was deﬁned as the
number of HIV-positive patients the physician had previously
treated at the time the study participant was enrolled into the
HIV/AIDS Drug Treatment Program. Estimates of adherence
to antiretroviral therapy are based on medications actually
dispensed, not prescribed. Patients receive new prescriptions
at various time intervals ranging from monthly to, at most,
every 3 mo. For this exercise we limited our measure of
adherence to the ﬁrst year of therapy and estimated it by
dividing the number of months of medications dispensed by
the number of months of follow-up.
Statistical Analyses
Cumulative mortality rates were estimated using Kaplan-
Meier methods. Event-free participants were right censored
as of June 30, 2003. Participants included in this analysis were
not followed after this date, and those lost to follow-up were
censored at the date of last known contact with the HIV/AIDS
Drug Treatment Program.
Cox proportional hazard regression was used to model the
simultaneous effect of prognostic variables on survival [16]. A
forward stepwise technique was used in the selection of
covariates. Interactions and non-proportionality of hazards
were explored in our modeling. The assumption of propor-
tional hazards was validated by inspection of log( log[survival
function]) estimates against log time plots.
In this analysis, a number of prognostic variables were
treated as time-dependent variables including the following:
protease inhibitor use, a diagnosis of AIDS, CD4 cell count,
plasma HIV-1 RNA levels, and drug resistance. Protease
inhibitor use (yes versus no), a diagnosis of AIDS (yes versus
no), plasma HIV-1 RNA levels (,100,000 versus  100,000
copies/ml), emergence of resistance to antiretrovirals (yes
versus no), and each class of resistance mutation (yes versus
no) were treated as binary time-dependent variables. In our
analysis we assumed that once resistance was detected, this
variable was not allowed to change values until the end of the
follow-up period. Other variables were measured at baseline
and treated as either categorical or continuous. Gender (male
versus female) and history of injection drug use (yes versus
no) were treated as ﬁxed binary variables. Age (in years) and
physician experience (per 100 patients followed) were treated
as continuous variables.
Marginal structural modeling was used to address potential
confounding between time-dependent variables in the Cox
proportional hazard regression models [17]. This potential
confounding occurs when there exists a time-dependent
covariate that is predictive of both mortality and the
explanatory variable, but is also predicted by the explanatory
variable itself. In this analysis, HIV-1 RNA is confounded with
the exposure of interest, drug resistance. Marginal structural
modeling is a form of causal analysis based upon counter-
factuals, the hypothetical difference between the observed
outcome for each individual and the unobserved outcomes
that would have arisen had they received a different exposure
history [18]. In essence, the model uses a series of logistic
regression steps incorporating the time-dependent variables
to weight the observations in such a way as to remove the
confounding effects of the time-dependent variables while
maintaining the original associations between the exposure
variables and outcome. Unbiased estimates of the causal
effect of exposure on the outcome can then be computed
using the estimated weights for each observation and baseline
predictors, provided that all important confounders have
been considered and that the models used to compute the
weights and the effects are properly speciﬁed [17]. HIV-1
RNA levels, CD4 cell count, AIDS diagnosis, and protease and
non-nucleoside inhibitor use were considered as potential
time-dependent confounders, while resistance to any class of
drug (yes versus no) was considered as a time-dependent
exposure. We also considered each separate class of mutation
as a binary time-dependent exposure while controlling for
the presence/absence of other mutations.
Analyses were performed using SAS software version 9.1.3
service pack 3 (SAS, Cary, North Carolina, United States). All
tests of signiﬁcance were two-sided, with a p-value of less than
0.05 indicating that an association was statistically signiﬁcant.
Results
Between August 1, 1996, and September 30, 1999, a total of
1,312 antiretroviral-naı ¨ve participants aged 18 y and over
initiated triple combination therapy consisting of two
nucleosides plus a protease inhibitor or a non-nucleoside
reverse transcriptase inhibitor. Of these, 121 (9.2%) were
excluded from this analysis for not having both baseline CD4
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prior to the start of antiretroviral therapy or for having
initiated therapy as part of a clinical trial. Among the
remaining 1,191 study participants, there were 679 patients
with HIV-drug-resistance genotyping done on samples of
plasma HIV-1 RNA before initiating HAART at the time of
this analysis. HIV-drug resistance to any class was observed in
53 (7.8%) of the patients. Among these patients, 39 (73.6%)
exhibited resistance to one class, ten (18.9%) to two classes,
and four (7.6%) to three classes. A total of 14 (26.4%)
exhibited mutations conferring resistance to lamivudine, 29
(54.7%) to other nucleoside reverse transcriptase inhibitors,
eight (15.1%) to non-nucleoside reverse transcriptase inhib-
itors, and 19 (35.8%) to protease inhibitors. These patients
exhibiting baseline resistance were excluded from the
analysis, and the total study sample was based on the
remaining 1,138 (86.7%) participants. Study participants
had HIV-1 RNA levels higher than those of individuals
excluded from the analysis (median viral load 87 versus 120
copies/ml; p , 0.001). No other signiﬁcant associations were
noted between the two groups.
Among the remaining HOMER participants (n ¼ 1,138), a
total of 229 (20.1%) patients achieved durable viral suppres-
sion (HIV-1 RNA levels , 1,000 copies/ml) during the entire
follow-up period. There were 776 (68.2%) patients with at
least one HIV-1 RNA level measurement at 1,000 copies/ml or
above that showed no detectable resistance during the follow-
up period, and we assumed these individuals had no drug
resistance. Although we systematically genotyped all samples
with HIV-1 RNA levels of 1,000 copies/ml or more during
follow-up, there were three (0.3%) patients for whom the
resistance test failed at least once for technical reasons, and
for these particular tests we assumed that no mutation was
detected.
Study participants were ﬁrst prescribed 26 different triple
combination antiretroviral regimens. Table 1 shows that over
half of these participants (848; 74.5%) initiated therapy with a
protease inhibitor, while the rest of the study participants
(290; 25.5%) had a regimen that included a non-nucleoside
reverse transcriptase inhibitor. A total of 123 (10.8%)
commenced therapy in 1996, 402 (35.3%) in 1997, 340
(29.9%) in 1998, and 273 (24.0%) in 1999. The median age
was 37 y (inter-quartile range: 32, 44 y), CD4 cell count was
280 cells/mm
3 (inter-quartile range: 130, 430 cells/mm
3),
plasma HIV-1 RNA level was 120,000 copies/ml (inter-quartile
range: 43,000, 310,500 copies/ml), physician experience was 44
patients per physician (inter-quartile range: 5, 131 patients
per physician). There were 317 (27.9%) participants who had
a history of injection drug use and 149 (13.1%) study
participants with a prior diagnosis of AIDS. Among all
participants, 956 were males (84.0%).
The overall median time of follow-up was 56.4 mo (inter-
quartile range: 45.8, 69.2 mo). The median number of CD4
count measurements was 3.59 per year (inter-quartile range:
2.24, 4.59 per year), and the median number of plasma HIV-1
RNA measurements was 3.44 per year (inter-quartile range:
2.56, 4.25 per year). A total of 17,632 CD4 cell counts and
17,358 HIV-1 RNA determinations were collected for
participants over the study period. The median numbers of
CD4 cell counts and HIV-1 RNA determinations per
participant were 15 (inter-quartile range: 7, 23) and 15
(inter-quartile range: 9, 21), respectively. In this study, a
switch in drug regimen was recorded when any modiﬁcation
(addition or removal) in the original drug regimen occurred.
Table 1. Baseline Characteristics of Patients Initiating Any Triple Combination Antiretroviral Therapy
Variable Subcategory Statistic




Gender (n [%]) Male 956 (84.0)
Female 182 (16.0)
Injection drug use history (n [%]) Yes 317 (27.9)
No 821 (72.1)
AIDS diagnosis (n [%]) Yes 149 (13.1)
No 989 (86.9)
Protease inhibitor use (n [%]) Yes 848 (74.5)
No 290 (25.5)




Class of non-nucleoside reverse inhibitor (n [%]) Nevirapine 272 (93.8)
Efavirenz 8 (2.8)
Delavirdine 10 (3.4)
Age (years) (median [inter-quartile range]) 37.0 (31.9, 43.5)
CD4 cell count (cells/mm
3) (median [inter-quartile range]) 280.0 (130.0, 430.0)
Plasma viral load (1,000 copies/ml) (median [inter-quartile range]) 120.0 (43.0, 310.0)
Physician’s experience
a (median [inter-quartile range]) 44.0 (5.0, 131.0)
aNumber of HIV-positive patients the physician had previously treated at the time the study participant was enrolled into the HIV/AIDS Drug Treatment Program.
DOI: 10.1371/journal.pmed.0030356.t001
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a median three times (inter-quartile range: 1, 5 times) over
the follow-up period. Protease inhibitors were added to or
removed from a regimen a median of one time (inter-quartile
range: 1, 3 times), non-nucleoside reverse transcriptase
inhibitors one time (inter-quartile range: 0, 2 times), and
nucleoside reverse transcriptase inhibitors three times (inter-
quartile range: 1, 5 times). The median time to ﬁrst switch was
7.8 mo (inter-quartile range: 2.1, 23.6 mo) in this study
population.
Drug-resistance testing was completed on a total 3,099
samples over the ﬁrst 30 mo of follow-up. A median of three
(inter-quartile range: 1, 5) samples were tested per partic-
ipant. HIV-drug resistance to any class was observed in 302
(28.5%) participants. Of these, 19 (6.3%) exhibited resistance
to all three classes, 137 (45.4%) to two classes, and 146 (48.3%)
to one class. A total of 221 (73.2%) exhibited mutations
conferring resistance to lamivudine, 98 (32.5%) to other
nucleoside reverse transcriptase inhibitors, 157 (52.0%) to
non-nucleoside reverse transcriptase inhibitors, and 66
(21.9%) to protease inhibitors. The median time to ﬁrst
emergence of resistance to any class of drug under study was
16.5 mo (inter-quartile range: 8, 27 mo).
Table 2 presents the association between baseline charac-
teristics, adherence during ﬁrst yea,r and emergence of
resistance. Persons who developed any mutations were more
likely to be injection drug users (p¼0.007), to have lower CD4
counts (p , 0.001), and to have higher plasma viral load (p ,
0.001) than persons who did not develop any resistance over
the ﬁrst 30 mo.
As of June 30, 2003, a total of 207 deaths were identiﬁed in
the study population over the follow-up period, with an
overall crude mortality rate of 18.2%. The product limit
estimate of the cumulative mortality rate at 12 and 24 mo was
4.4% (60.6%) and 8.7% (60.8%), respectively. Of these
deaths, 30 (14.5%) were to patients who exhibited resistance
to one class, 26 (12.6%) to two classes, and one (0.5%) to three
classes. A total of 41 (19.8%) deaths were to patients who
exhibited resistance to lamivudine, 15 (7.3%) to other
nucleosides, 32 (15.5%) to non-nucleoside reverse tran-
scriptase inhibitors, and six (2.9%) to protease inhibitors.
Nearly, three-quarters of the deaths involved no resistance to
any class of drug (150; 72.5%).
The univariable and multivariable analyses of the baseline
and time-dependent factors associated with all cause mortal-
ity are presented in Table 3 through four different models. In
the univariable analysis for baseline characteristics (Model 1),
only age, a prior AIDS diagnosis, protease inhibitor use,
physician experience, CD4 count, and HIV-1 RNA level were
associated with mortality. When we considered time-depend-
ent factors, the univariable analysis (Model 2) showed us that
age, baseline drug combination, physician experience, a prior
AIDS diagnosis, protease inhibitor use, adherence, CD4 cell
count, HIV-1 RNA level, and resistance to any antiretroviral
were associated with mortality. We also observed that
resistance to some classes of drug, more speciﬁcally to
lamivudine and non-nucleoside reverse transcriptase inhib-
itors, were also associated with mortality. After controlling
for other prognostic explanatory variables, Model 3 shows
that there is a strong association between emergence of any
resistance and risk of death (hazard ratio: 1.58 [95%
conﬁdence interval (CI): 1.14, 2.20]). The heterogeneity in
the association between resistance and mortality also depends
on the type of resistance that was acquired (Model 4), with
persons who exhibited resistance to non-nucleoside reverse
transcriptase inhibitors being 2.57 times (95% CI: 1.74, 3.78)
more likely to die.
The same analyses were repeated with non-accidental
deaths as the outcome of interest (n¼160; 77.3%). Individuals
dying from non-accidental deaths in the study had less
experienced physicians (median: 16 patients per physician
[inter-quartile range: 2, 81 patients per physician]), worse
CD4 cell counts (median: 150 cells/mm
3 [inter-quartile range:
45, 310 cells/mm
3]), and higher viral load levels (median:
175,000 copies/ml [inter-quartile range: 88,000, 405,000
copies/ml]) than the individuals included in the all cause
Table 2. Associations between Baseline Variables and Emergence of Any Resistance in 1,138 Participants First Prescribed Any Triple
Combination Antiretroviral Therapy
Variable Subcategory Emergence of Any Resistance
Yes No p-Value
Gender (n [%]) Male 251 (83.1) 705 (84.3) 0.621
Female 51 (16.9) 131 (15.7)
Injection drug use history (n [%]) Yes 102 (33.8) 215 (25.7) 0.007
No 200 (66.2) 621 (74.3)
AIDS diagnosis (n [%]) Yes 42 (13.9) 107 (12.8) 0.625
No 260 (86.1) 729 (87.2)
Protease inhibitor use (n [%]) Yes 223 (73.8) 625 (74.8) 0.753
No 79 (26.2) 211 (25.2)
Adherence (n [%]) ,75% 68 (22.5) 226 (27.0) 0.124
 75% 234 (77.5) 610 (73.0)
Adherence (median [inter-quartile range]) 92.0 (75.0, 100.0) 100.0 (67.0, 100.0) 0.184
Age (years) (median [inter-quartile range]) 36.5 (31.8, 42.5) 37.2 (31.9, 43.9) 0.218
CD4 cell count (cells/mm
3) (median [inter-quartile range]) 220.0 (100.0, 370.0) 300.0 (140.0, 440.0) ,0.001
Plasma viral load (1,000 copies/ml) (median [inter-quartile range]) 170.0 (88.0, 424.0) 104.0 (33.0, 260.0) ,0.001
Physician’s experience (median [inter-quartile range]) 42.5 (4.0, 128.0) 45.0 (5.0, 132.0) 0.511
DOI: 10.1371/journal.pmed.0030356.t002
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Emergence of Drug Resistance and Mortalitymortality (see Table 1). When we assessed the association
between survival and resistance in this population we
observed that persons who exhibited reduced sensitivity to
any antiretroviral had death rates that were 1.51 times (95%
CI: 1.04, 2.20) higher than those who did not exhibit
resistance. We also looked at the individuals dying via
accidental death (n ¼ 47; 22.7%). These individuals had more
experienced physicians (median: 53 patients per physician
[inter-quartile range: 12, 131 patients per physician]), better
CD4 cell counts (median: 300 cells/mm
3 [inter-quartile range:
210, 470 cells/mm
3]), and lower viral load levels (median:
129,000 copies/ml [inter-quartile range: 39,000, 210,000
copies/ml]) than the individuals included in the all cause
mortality (see Table 1). When we assessed the association
between survival and emergence of resistance in this
population we observed that the hazard ratio was 1.83 (95%
CI: 0.92, 3.63).
Table 4 presents the ﬁnal marginal structural models of the
causal effect of drug resistance on mortality. In all models, the
time-dependent confounders were protease inhibitor/non-
nucleoside experience, AIDS diagnosis, CD4 cell count, viral
load, and HAART regimen. The exposures of main interest
were emergence of any resistance, and emergence of
resistance to each separate class of mutation (lamivudine,
other nucleosides, non-nucleosides, and protease inhibitors).
Model 1 considers the emergence of any resistance as the
exposure of main interest. The results show that persons who
developed any resistance had death rates that were 1.75 times
(95% CI: 1.27, 2.43) higher than those who did not exhibit any
resistance. When we considered each separate class of
mutation as the exposure of interest (Models 2–5), while
controlling for the presence/absence of other mutations, we
observed that those persons who exhibited reduced sensitivity
to non-nucleoside reverse transcriptase inhibitors had the
highest risk: they were 3.02 times (95% CI: 1.99, 4.57) more
likely to die than those who did not exhibit this type of
resistance.
Discussion
Our results demonstrate that emergence of resistance to
non-nucleoside reverse transcriptase inhibitors was associ-
ated with a greater risk of subsequent death than was
emergence of resistance to any other class of drug. Our
ﬁnding that resistance to non-nucleoside reverse transcrip-
tase inhibitors was signiﬁcantly associated with mortality even
after adjustment for plasma HIV-1 RNA levels, adherence,
and CD4 cell counts suggests resistant viruses may have
differences in ﬁtness [19]. Resistance to non-nucleoside
reverse transcriptase inhibitor therapy has also previously
been shown to occur at low to moderate levels of adherence,
indicating that non-nucleoside reverse transcriptase resist-
ance may be an independent marker for poor adherence in
our population [20]. Mortality was not associated with viruses
resistant to protease inhibitors, lamivudine, or other nucleo-
side reverse transcriptase inhibitors.
The emergence of drug resistance to antiretrovirals in this
drug-naı ¨ve cohort remains low [8]. The median time to ﬁrst
Table 3. Univariable and Multivariable Analyses of the Baseline and Time-Dependent Factors Associated with Survival among 1,138
Persons First Prescribed Any Triple Combination Antiretroviral Therapy









Age (years) 1.03 (1.02, 1.04) 1.03 (1.02, 1.04) 1.04 (1.03, 1.06) 1.04 (1.02, 1.06)
Gender (male versus female) 1.15 (0.81, 1.65) 1.15 (0.81, 1.65) — —
Baseline drug combination (PI versus NNRTI) 1.44 (1.01, 2.06) 1.44 (1.01, 2.06) NS NS
Physician experience (per 100 patients) 0.70 (0.58, 0.85) 0.70 (0.58, 0.85) NS NS
AIDS diagnosis (yes versus no) 1.46 (1.02, 2.09) 1.53 (1.09, 2.14) NS NS
Injection drug use (yes versus no) 1.19 (0.89, 1.60) 1.19 (0.89, 1.60) — —
Adherence (,75% versus  75%) — 2.20 (1.66, 2.90) 1.59 (1.17, 2.16) 1.54 (1.14, 2.08)
CD4 cell count (cells/mm
3)  200 1.00 (—) 1.00 (—) 1.00 (—) 1.00 (—)
50–199 1.96 (1.43, 2.68) 3.25 (2.28, 4.62) 2.51 (1.75, 3.60) 2.53 (1.76, 3.63)
,50 2.95 (2.07, 4.19) 17.24 (12.54, 23.69) 11.74 (8.27, 16.67) 11.78 (8.29, 16.75)
Plasma viral load (copies/ml) ,100,000 1.00 (—) 1.00 (—) 1.00 (—) 1.00 (—)
 100,000 1.57 (1.17, 2.10) 4.50 (3.37, 5.99) 1.91 (1.38, 2.65) 1.93 (1.39, 2.68)
PI experience (yes versus no) — 1.77 (1.18, 2.65) NS NS
Non-nucleoside experience (yes versus no) — 1.24 (0.94, 1.64) — —
Emergence of resistance (yes versus no) — 1.97 (1.43, 2.70) 1.58 (1.14, 2.20) —
Lamivudine (yes versus no) — 1.77 (1.24, 2.51) — NS
Other nucleosides (yes versus no) — 1.46 (0.86, 2.48) — NS
Non-nucleosides (yes versus no) — 2.57 (1.74, 3.78) — 1.55 (1.03, 2.32)
PIs (yes versus no) — 0.85 (0.38, 1.93) — NS
Dashes indicate that that variable was not included in the analysis. Model 1 refers to the univariable survival analysis of baseline characteristics. Model 2 refers to the univariable survival
analysis of baseline and time-dependent characteristics. The time-dependent confounders were protease inhibitor experience, non-nucleoside experience, AIDS diagnosis, CD4 cell count,
and viral load. The exposures of main interest were emergence of any resistance, and emergence of resistance to each class of drugs (lamivudine, other nucleosides, non-nucleosides, and
protease inhibitors). Model 3 refers to the multivariable analysis of variables that were significant in Model 2. However, emergence of any resistance in this model was considered as a
dichotomous variable. Model 4 refers to the multivariable analysis of variables that were significant in Model 2. However, emergence of resistance in this model was considered as a
dichotomous variable for each class of mutation.
NNRTI, non-nucleoside reverse transcriptase inhibitor; NS, not significant; PI, protease inhibitor.
DOI: 10.1371/journal.pmed.0030356.t003
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Emergence of Drug Resistance and Mortalityemergence of resistance to any class of drug was just over a
year. HIV-drug resistance to any class was observed in just
over a quarter of participants over 30 mo, with less than 10%
of patients exhibiting resistance to all three classes. In
contrast to other studies that included both therapy-naı ¨ve
and experienced patients [6], our results are likely much
closer to true levels of multiple drug resistance in a
population initiating HAART.
Most patients in our study died with wild-type virus. Nearly,
three-quarters of the deaths were of patients who exhibited
no resistance to any class of drug, and less than 2% exhibited
resistance to all three classes. Such patients may have had
insufﬁcient drug exposure because of poor adherence, thus
selecting for resistant virus. We have previously shown
signiﬁcant differences in survival among adherent and non-
adherent patients at all levels of CD4 count, with a
particularly dramatic impact on survival in patients with
highly advanced disease [9]. These ﬁndings are independent
of whether the measurement of adherence is based on
prescription reﬁlls or antiretroviral concentrations in un-
timed plasma samples [9,21–23]. Similarly, in an indigent
cohort in San Francisco, the level of adherence was closely
associated with longitudinal viral suppression and the rate of
subsequent disease progression [24].
Two recent studies have reported on the association
between drug resistance and risk of death [8,25]. Lucas et al.
[25], based on a cohort of non-naı ¨ve individuals starting
HAART, found that emergence of resistance was not linked
to increased mortality rates in a multivariable analysis,
adjusting for prognostic factors such as HIV-1 exposure
group, CD4 cell count at resistance testing, mean log10 HIV-1
RNA level during prior treatment with HAART, and whether
or not HAART was used during the 6 mo following resistance
testing. There are two important differences between this
study and ours. First, Lucas et al. failed to control for several
other important ﬁxed and time-varying confounder factors
that could have inﬂuenced their results, such as adherence,
HAART regimen, and injection drug use, to cite a few.
Second, they did not exclude from the analysis individuals
who had received HAART previously, and who had already
presented some type of mutation, which could have poten-
tially biased their results. Another study, by Recsky et al. [8],
based on a subpopulation of individuals from our study that
died between July 1997 and December 2001, also failed to
demonstrate an association between drug resistance and
mortality. The authors of this latter paper used univariable
analyses to compare the presence or absence of resistance at
the time of death across several characteristics: age (at
initiation of HAART and at death), sex, injection drug use
status, CD4 cell count and plasma HIV-1 RNA level at the
time right before the genotype test, adherence, and time
undergoing treatment. The only difference they found
between these two groups was due to the duration of
treatment, where individuals who presented any drug
resistance had longer median duration of therapy than those
without any resistance (32 versus 15 mo; p , 0.001). We
believe that the differences among the results of these two
studies and ours are due to differences between study
populations (e.g., comparison groups and deﬁnitions of
cohort) and differences in methodology used to assess the
relationship between outcome and exposures.
Although we concluded that emergence of resistance was
strongly associated with elevated risk of mortality, there are
two important potential sources of bias that could explain
our results. First, HOMER patients with samples of HIV-1
RNA of less than 1,000 copies/ml during the entire follow-up












Age (years) 1.04 (1.02, 1.05) 1.04 (1.02, 1.05) 1.04 (1.02, 1.05) 1.02 (1.00, 1.04) 1.04 (1.02, 1.05)
Gender (male versus female) NS NS NS NS NS
PI experience (yes versus no) NS NS NS NS NS
Physician experience
(per 100 patients)
0.78 (0.64, 0.95) 0.57 (0.41, 0.81) 0.78 (0.64, 0.95) 0.86 (0.70, 1.05) 0.78 (0.64, 0.95)
AIDS diagnosis (yes versus no) NS NS NS NS NS
Injection drug use (yes versus no) NS NS NS NS NS
Adherence (,75% versus  75%) 2.88 (2.12, 3.91) 3.16 (2.24, 4.45) 2.89 (2.13, 3.94) 2.22 (1.53, 3.23) 2.92 (2.14, 3.98)
CD4 cell count (cells/mm
3)  200 1.00 (—) 1.00 (—) 1.00 (—) 1.00 (—) 1.00 (—)
50–199 1.90 (1.35, 2.69) 2.25 (1.51, 3.35) 1.98 (1.40, 2.79) 2.23 (1.54, 3.24) 2.01 (1.43, 2.84)
,50 3.17 (2.11, 4.76) 3.62 (2.33, 5.62) 3.26 (2.15, 4.93) 3.30 (2.19, 4.99) 3.32 (2.20, 5.01)
Plasma viral load (copies/ml) ,100,000 1.00 (—) 1.00 (—) 1.00 (—) 1.00 (—) 1.00 (—)
 100,000 1.17 (0.85, 1.60) 1.15 (0.83, 1.60) 1.25 (0.92, 1.71) 1.27 (0.91, 1.77) 1.28 (0.94, 1.74)
Emergence of resistance
(yes versus no)
1.75 (1.27, 2.43) — — — —
Lamivudine (yes versus no) — 1.32 (0.81, 2.14) — — —
Other nucleosides (yes versus no) — — 1.40 (0.80, 2.45) — —
Non-nucleosides (yes versus no) — — — 3.02 (1.99, 4.57) —
PIs (yes versus no) — — — — 0.62 (0.27, 1.42)
Dashes indicate that that variable was not included in the analysis. In each model the time-dependent confounders were protease inhibitor/non-nucleoside experience, AIDS diagnosis,
CD4 cell count, and viral load. The exposures of main interest were emergence of any resistance, and emergence of resistance to each separate class of drugs (lamivudine, other
nucleosides, non-nucleosides, and protease inhibitors). Model 1 had emergence of any resistance as the exposure of main interest. Models 2–5 considered each class of mutation
separately as the exposure of interest, controlling for the presence of other mutations.
NS, not significant; PI, protein inhibitor.
DOI: 10.1371/journal.pmed.0030356.t004
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Emergence of Drug Resistance and Mortalityperiod (n ¼ 229; 20.1%) were assumed to have no drug-
resistance mutations. We therefore conducted a sensitivity
analysis restricted to patients with plasma viral load levels of
1,000 copies/ml or more to assess the impact of this
assumption on our results and the robustness of the marginal
structural models in dealing with this possible source of bias.
We observed that patients who showed the emergence of any
resistance were 1.68 times (95%CI: 1.19, 2.38) more likely to
die than those who did not, which is consistent with the
results found in our original analysis. Second, in the present
study we did not exclude patients who achieved durable viral
elevation (HIV-1 RNA levels   1,000 copies/ml) during the
entire follow-up period (n ¼ 130; 11.4%). To assess whether
this group drove our mortality trends, and not emergence of
resistance per se, we conducted a second sensitivity analysis
restricted to patients with no durable viral elevation. We
observed that those patients that developed any type of
resistance were 2.09 times (95%CI: 1.41, 3.10) more likely to
die than those who did not, which is also consistent with our
previous results.
There are several features of our study that should be
highlighted. First, our study was carried out within a
province-wide treatment program, in which all individuals
had access to medical attention, combination antiretroviral
therapy, and laboratory monitoring free of charge. We are
conﬁdent, therefore, that our results are not inﬂuenced by
access to therapy, a factor that has often compromised the
interpretation of similar population- and cohort-based
studies. Second, this study was based on treatment-naı ¨ve
individuals, thus our results are not confounded by previous
therapy use. Third, delayed reporting was not likely a factor;
as the vast majority of deaths are reported within 3 mo of
death through active follow-up with physicians and hospitals
and regular linkages. Finally, although we adjusted our
analyses for pertinent demographic and clinical character-
istics, like all studies of patients treated in observational
cohorts, unmeasured differences may exist among study
populations, and for this reason caution is warranted.
In summary, we demonstrated that emergence of resistance
to non-nucleoside reverse transcriptase inhibitors was asso-
ciated with a greater risk of subsequent death than was
emergence of resistance to other drug classes. Future
research is needed to identify the particular subpopulations
of men and women at greatest risk. These efforts also need to




The GenBank (http://www.ncbi.nlm.nih.gov/Genbank) accession
number for HIV HXB2 is K03455.
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Emergence of Drug Resistance and MortalityEditors’ Summary
Background. In the 1980s, infection with the human immunodeficiency
virus (HIV) was effectively a death sentence. HIV causes AIDS (acquired
immunodeficiency syndrome) by replicating inside immune system cells
and destroying them, which leaves infected individuals unable to fight
off other viruses and bacteria. The first antiretroviral drugs were
developed quickly, but it soon became clear that single antiretrovirals
only transiently suppress HIV infection. HIV mutates (accumulates
random changes to its genetic material) very rapidly and, although
most of these changes (or mutations) are bad for the virus, by chance
some make it drug resistant. Highly active antiretroviral therapy (HAART),
which was introduced in the mid-1990s, combines three or four
antiretroviral drugs that act at different stages of the viral life cycle.
For example, they inhibit the reverse transcriptase that the virus uses to
replicate its genetic material, or the protease that is necessary to
assemble new viruses. With HAART, the replication of any virus that
develops resistance to one drug is inhibited by the other drugs in the
mix. As a consequence, for many individuals with access to HAART, AIDS
has become a chronic rather than a fatal disease. However, being on
HAART requires patients to take several pills a day at specific times. In
addition, the drugs in the HAART regimens often have side effects.
Why Was This Study Done? Drug resistance still develops even with
HAART, often because patients don’t stick to the complicated regimens.
The detection of resistance to one drug is usually the prompt to change
a patient’s drug regimen to head off possible treatment failure. Although
most patients treated with HAART live for many years, some still die from
AIDS. We don’t know much about how the emergence of drug-resistance
mutations affects mortality in patients who are starting antiretroviral
therapy for the first time. In this study, the researchers looked at how the
emergence of drug resistance affected survival in a group of HIV/AIDS
patients in British Columbia, Canada. Here, everyone with HIV/AIDS has
access to free medical attention, HAART, and laboratory monitoring, and
full details of all HAART recipients are entered into a central reporting
system.
What Did the Researchers Do and Find? The researchers enrolled
people who started antiretroviral therapy for the first time between
August 1996 and September 1999 into the HAART Observational Medical
Evaluation and Research (HOMER) cohort. They then excluded anyone
who was infected with already drug-resistant HIV strains (based on the
presence of drug-resistance mutations in viruses isolated from the
patients) at the start of therapy. The remaining 1,138 patients were
followed for an average of five years. All the patients received either two
nucleoside reverse transcriptase inhibitors and a protease inhibitor, or
two nucleoside and one non-nucleoside reverse transcriptase inhibitor
(NNRTI). Nearly a fifth of the study participants died during the follow-up
period. Most of these patients actually had drug-sensitive viruses,
possibly because they had neglected taking their drugs to such an extent
that there had been insufficient drug exposure to select for drug-
resistant viruses. In a quarter of the patients, however, HIV strains
resistant to one or more antiretroviral drugs emerged during the study
(again judged by looking for mutations). Detailed statistical analyses
indicated that the emergence of any drug resistance nearly doubled the
risk of patients dying, and that people carrying viruses resistant to
NNRTIs were three times as likely to die as those without resistance to
this class of antiretroviral drug.
What Do These Findings Mean? These results provide new information
about the emergence of drug-resistant HIV during HAART and possible
effects on the long-term survival of patients. In particular, they suggest
that clinicians should watch carefully for the emergence of resistance to
NNRTIs in their patients. Because this type of resistance is often due to
poor adherence to drug regimens, these results also suggest that
increased efforts should be made to ensure that patients comply with
the prescribed HAART regimens, especially those whose antiretroviral
therapy includes NNRTIs. As with all studies in which a group of
individuals who share a common characteristic are studied over time, it is
possible that some other, unmeasured difference between the patients
who died and those who didn’t—rather than emerging drug resist-
ance—is responsible for the observed differences in survival. Additional
studies are needed to confirm the findings here, and to investigate
whether specific subpopulations of patients are at particular risk of
developing drug resistance and/or dying during HAART.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030356.
  US National Institute of Allergy and Infectious Diseases fact sheet on
HIV infection and AIDS
  US Department of Health and Human Services information on AIDS,
including details of approved drugs for the treatment of HIV infection
  US Centers for Disease Control and Prevention information on HIV/
AIDS
  Aidsmap, information on HIV and AIDS provided by the charity NAM,
which includes details on antiretroviral drugs
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